Clinical Trials Logo

Respiratory Tract Diseases clinical trials

View clinical trials related to Respiratory Tract Diseases.

Filter by:

NCT ID: NCT04467190 Completed - Respiratory Disease Clinical Trials

Investigation of Inflammacheck to Measure Exhaled Breath Condensate Hydrogen Peroxide in Respiratory Conditions

VICTORY
Start date: September 13, 2019
Phase:
Study type: Observational

People with lung conditions can suffer significantly with their symptoms and often require multiple trips to their GP or secondary care before a diagnosis is made. It can be difficult to diagnose lung disease and to differentiate between different lung conditions, so many people may be misdiagnosed or incorrectly not given a diagnosis. The tests currently used to diagnose lung diseases can be difficult or uncomfortable to do, especially if the person is experiencing lots of symptoms, and therefore can give poor or unreliable results.A new quick and easy to perform test is needed that can differentiate between various lung conditions and people with no lung disease, that can be performed in primary and secondary care with immediate results.

NCT ID: NCT04413292 Completed - Clinical trials for Bronchial Neoplasm Benign

Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases

Start date: January 1, 2017
Phase:
Study type: Observational

Purpose: Survivin is a common member of the inhibitors of the apoptosis protein (IAP) family with a dual role in promoting cell proliferation and preventing apoptosis. Fibulin-3, a matrix glycoprotein, was recently presented as a promising novel biomarker for malignant pleural mesothelioma. The aim of this study was to validate the expression levels of survivin and fibulin-3 in benign and malignant respiratory diseases. Patients and methods: The study included 73 patients, with various benign and malignant respiratory diseases. For validation of the data, a control group including 20 healthy subjects was chosen. The clinical and radiological assessments of the included individuals were done. The serum survivin and fibulin-3 levels were measured using ELISA assays kits, while their local expressions in the lung and pleura were assessed using western blot analysis.

NCT ID: NCT04407806 Completed - Asthma in Children Clinical Trials

Utility of Continuous Pulse Oximetry for Pediatric Patients With Stable Respiratory Illness

Start date: December 24, 2020
Phase: N/A
Study type: Interventional

This is a randomized, prospective study to determine if there is a difference in hospital length of stay between patients receiving continuous hardwire cardiorespiratory monitoring and those receiving intermittent vital signs measurements among pediatric patients admitted for uncomplicated respiratory illness.

NCT ID: NCT04407169 Completed - COVID Clinical Trials

Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease

CRITICoVid
Start date: June 1, 2020
Phase:
Study type: Observational

A new Coronavirus (SARS-CoV-2) emerged in Wuhan Province, China in December 2019 and rapidly spread around the world. To date, the data in the literature regarding the clinical and epidemiological characteristics of severe forms of CoVid-19 in patients with chronic respiratory disease are not well known. The hypothesis is that patients with chronic respiratory disease (COPD, asthma, bronchial dilatations, pulmonary hypertension, cystic fibrosis, obesity-hypoventilation syndrome, obstructive sleep apnea syndrome) infected with SARS-Cov-2 will have increased dyspnea and hypoxemia leading to hospitalization for severe forms more frequently than the general population. However, they do not appear to be more at risk of developing a critical form. This study is carried out in order to propose to estimate the prevalence of critical forms of CoVid19 among patients with chronic respiratory diseases hospitalized for severe forms.

NCT ID: NCT04394117 Completed - COVID-19 Clinical Trials

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease

CLARITY
Start date: June 19, 2020
Phase: Phase 4
Study type: Interventional

The Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY) study is a pragmatic prospective, open-label, randomised controlled trial. CLARITY aims to examine the effectiveness of angiotensin II receptor blockers (ARBs) on improving the outcomes of people who tested positive for COVID-19 disease.

NCT ID: NCT04388579 Completed - Respiratory Disease Clinical Trials

Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation Because of COVID-19

PRAISE@COVID
Start date: March 20, 2020
Phase:
Study type: Observational

This study applied the Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE) on respiratory patients who had their on-going ambulatory Pulmonary Rehabilitation program interrupted due to the COVID-19 outbreak. The research hypothesis is that ranking patients' self-efficacy is a useful screening tool to support patients' follow-up on a Pulmonary Rehabilitation telehealth solution to be explored during the COVID-19 outbreak.

NCT ID: NCT04386408 Completed - Immune Response Clinical Trials

Evaluation of the Effect of a Combination of Plant Extracts (BSL_EP027) on the Incidence of Respiratory Infections

Start date: November 30, 2019
Phase: Phase 1
Study type: Interventional

The objective of the present study is to evaluate the effectiveness of daily consumption of a Combination of Plant Extracts (BSL_EP027) on the incidence of respiratory infection symptoms and their duration in older healthy volunteers living in a nursing home.

NCT ID: NCT04375293 Completed - Chronic Rhinitis Clinical Trials

Characterisation of the Nasal Microbiome in Patients With N-ERD

MicroNERD
Start date: January 7, 2020
Phase: N/A
Study type: Interventional

Chronic rhinosinusitis (CRS) with (w) and without (s) nasal polyps (NP) in its different shapes is currently affecting up to 16% of the total population of the United States and around 11% of the population in Europe. It may also be associated with a hypersensitivity to non-steroidal anti-inflammatory (NSAID) drugs in a syndrome called NSAID-exacerbated respiratory disease (N-ERD) characterized by highly recurrent polyps and concomitant asthma. The pathophysiological mechanisms especially with regards to the potential role of the microbiome in driving N-ERD are so far not fully understood. Here, the investigators plan to analyse the nasal microbiome in these patients and to compare it to nasal samples from CRSwNP and CRSsNP patients as well as healthy controls (in total 80 subjects). This will provide insights into potential differences in the microbiome as compared to other CRS patients and the impact of the microbiome in driving this disease.

NCT ID: NCT04373070 Completed - Copd Clinical Trials

Quality-of-Life Management for COPD Patients

CAir
Start date: February 3, 2021
Phase: N/A
Study type: Interventional

The investigators aim to investigate the effects of a telemonitoring and chatbot-based application of "Living well with COPD" (CAir) on health-related quality-of-life in patients with COPD.

NCT ID: NCT04371471 Completed - Covid19 Clinical Trials

Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection

STC-19
Start date: March 1, 2020
Phase:
Study type: Observational

During this pandemic period, the goal of the health care system is to optimize the use of intensive care services for patients infected with SARS-CoV-2, given the frequency of complications that can lead to high mortality. When patients with suspected or confirmed COVID-19 are admitted to hospital, whether or not they are symptomatic, there is currently no method to predict who will progress to complications requiring the use of intensive measures in 24-48 hours.